Ruboxistaurin: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 123 patients receiving angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), 32 mg daily ruboxistaurin ...